老年支气管哮喘患者免疫功能、炎症因子和25-羟维生素D3的水平

目的探讨老年支气管哮喘患者免疫功能、细胞炎症因子和25-羟维生素D3[25-(OH)VD3]水平变化。方法选择老年支气管哮喘患者71例作为观察组;另选同期健康体检者58例作为对照组。所有研究对象采集外周静脉血,分离血清,采用流式细胞术测定CD3~+、CD4~+及CD4~+/CD8~+,采用免疫比浊法测定免疫球蛋白(Ig)A、Ig G、Ig M含量,采用酶联免疫吸附法(ELISA)测定白细胞介素(IL)-2、IL-4、IL-5和25-(OH)VD3含量。结果观察组第1秒用力呼气容积(FEV1)与预计值百分比(FEV1%)和FEV1/用力肺活量(FVC)明显低于对照组(均P<0.05);观察组CD3~+、CD4~+和CD4~+/CD8~+明显低于对照组(均P<0.05);观察组血清Ig A、Ig G和Ig M水平明显低于对照组(均P<0.05);观察组血清IL-2水平明显低于对照组,而IL-4和IL-5水平明显高于对照组(均P<0.05);观察组血清25-(OH)VD3水平明显低于对照组(P<0.05)。结论老年支气管哮喘患者免疫功能明显下降,且25-(OH)VD3明显降低,对预测和诊疗具有重要意义。     

重庆老年患者血清25-羟维生素D水平调查

目的调查重庆西南医院老年科住院患者血清25-羟维生素D状况。方法对住院老年患者行问卷调查,测定空腹血清25-羟维生素D含量,采用SPSS13.0软件对所得数据进行统计学处理。结果共调查342例住院患者,血清25-羟维生素D测定值为(14.62±7.96)ng/mL,血清25-羟维生素D水平与性别和年龄无相关性,维生素D缺乏和不足者占住院老年患者的93.27%,维生素D充足者6.72%。补充钙剂组患者血清25-羟维生素D水平均高于未补钙组,差异有统计学意义。补充活性维生素D组患者与未补充活性维生素D组血清25-羟维生素D水平差异无统计学意义。结论重庆市老年住院患者普遍缺乏维生素D,常规监测血清25-羟维生素D含量和积极预防和治疗维生素D缺乏十分必要。     

成人支气管哮喘患者血清25-羟维生素D_3水平及其与肺功能的关系

目的了解成人支气管哮喘(简称哮喘)患者血清25-羟维生素D3[25(OH)D3]水平,为哮喘的治疗提供新的策略。方法收集门诊确诊哮喘患者162例,通过电化学发光法检测患者血清25(OH)D3浓度,以德国JAEGER肺功能仪检测哮喘患者用力肺活量(FVC)、第1秒用力呼气容积(FEV1),计算第1秒用力呼气容积占预计值百分比(FEV1%pred)、FEV1/用力肺活量。根据患者FEV1情况行支气管激发或舒张试验。对25(OH)D3与乙酰甲胆碱PD20FEV1(PD20MCH-FEV1)、FEV1增加值、FEV1增加率的相关性进行分析。结果哮喘患者血清25(OH)D3浓度均低于正常参考值。支气管激发试验中,25(OH)D3与PD20MCH-FEV1呈正相关(P0.001,r=0.73);支气管舒张试验中,25(OH)D3与FEV1增加值及增加率均呈正相关(r分别为0.53、0.59,P值均0.01)。结论成人哮喘患者血清25(OH)D3浓度比正常值低;血清25(OH)D3浓度与哮喘患者气道高反应性呈负相关,与β2受体激动剂作用后气道阻塞的改善情况呈正相关。     

成人过敏性难治性支气管哮喘患者血清维生素D水平的相关临床研究

目的 研究成人难治性过敏性支气管哮喘(简称哮喘)患者血清维生素D水平以及和肺功能、总免疫球蛋白E、气道反应性,总免疫球蛋白E和气道反应性的相关性研究.方法 选择有过敏性哮喘病史的患者,测定肺功能及舒张试验,阳性者采用Uni CAP系统测定总免疫球蛋白E及特异性IgE,采用酶联免疫法测定体内维生素D主要的储存形式25羟维生素D3[25(OH)D3]含量,比较25(OH)D3水平和肺功能、总免疫球蛋白E、气道反应性的相关性以及总免疫球蛋白E和气道反应性相关性.结果 哮喘患者血清25(OH)D3含量明显低于正常值(23.10±23.15),且男女之间差异无统计学意义;血清25(OH)D3与FEV1％pred呈明显正相关(r=0.428,P＜0.01);和总免疫球蛋白E无明显相关性(r=-0.265,P＞0.01);和气道反应性呈明显负相关(r=-0.559,P＜0.01);总免疫球蛋白E和气道反应性呈明显正相关(r=0.578,P＜0.01).结论 成人难治性过敏性哮喘患者血清25(OH)D3明显低于正常水平,对于总免疫球蛋白E虽然无明显影响,但明显影响着患者的肺功能及气道的反应性.     

血清25-羟基维生素D3浓度水平与成人支气管哮喘及COPD的相互关系

目的通过检测支气管哮喘、COPD患者血清25（OH）D3水平,分析其与两种疾病的关系。方法随机选择哮喘患者59例、COPD患者35例,与之年龄、性别等相仿的健康对照组49例。通过电化学发光法检测25（OH）D3水平,并分析成人哮喘及COPD患者与对照组血清25（OH）D3水平的差异性。检测哮喘患者肺功能指标,分析与25（OH）D3水平相关性,以P〈0．05为有统计学意义。结果病例组血清25（OH）D3水平低于对照组,差异有统计学意义（P〈0．05）,哮喘患者血清25（OH）D,水平与FEV1、FEV1／FVC、FVC实测值之间无相关性（P〉0．05）。结论支气管哮喘及COPD患者均普遍存在维生素D缺乏现象。在成人支气管哮喘患者低的25（OH）D3水平与其肺功能之间无相关性。     

2型糖尿病患者血清25-羟维生素D水平的调查与分析

目的调查2型糖尿病(T2DM)患者血清25-羟维生素D[25(OH)D]水平,并分析25(OH)D和糖尿病之间的相关性。方法选择2016年10月-2018年9月期间该院收治的80例T2DM患者并作为试验组,另选择同期体检健康的志愿者100名作为对照组,检测两组入选对象血清25(OH)D水平及相关临床及生化指标。结果试验组病例25(OH)D低于对照组,FBG、SDP、SBP、BUN、TG水平高于对照组,差异有统计学意义(P<0.05);将试验组病例分为不同年龄组,发现男、女性年龄≥70岁年龄组25(OH)D水平最高,分别为(39.69±17.33)mmol/L、(38.04±16.55)mmol/L,相同年龄段中男女25(OH)D水平差异有统计学意义(P<0.05);且相关性分析表明,25(OH)D水平和空腹血糖之间存在负相关性(P<0.05)。结论T2DM患者血清25(OH)D水平低于正常者,通常情况下年龄越大25(OH)D水平越高;空腹血糖水平越高,25(OH)D水平越低。     

成人过敏性难治性支气管哮喘患者血清维生素D水平的相关临床研究

目的研究成人难治性过敏性支气管哮喘(简称哮喘)患者血清维生素D水平以及和肺功能、总免疫球蛋白E、气道反应性,总免疫球蛋白E和气道反应性的相关性研究。方法选择有过敏性哮喘病史的患者,测定肺功能及舒张试验,阳性者采用UniCAP系统测定总免疫球蛋白E及特异性IgE,采用酶联免疫法测定体内维生素D主要的储存形式25羟维生素D3[25(OH)D3]含量,比较25(OH)D3水平和肺功能、总免疫球蛋白E、气道反应性的相关性以及总免疫球蛋白E和气道反应性相关性。结果哮喘患者血清25(OH)D3含量明显低于正常值(23.10±23.15),且男女之间差异无统计学意义;血清25(OH)D3与FEV1%pred呈明显正相关(r=0.428,P0.01);和总免疫球蛋白E无明显相关性(r=-0.265,P0.01);和气道反应性呈明显负相关(r=-0.559,P0.01);总免疫球蛋白E和气道反应性呈明显正相关(r=0.578,P0.01)。结论成人难治性过敏性哮喘患者血清25(OH)D3明显低于正常水平,对于总免疫球蛋白E虽然无明显影响,但明显影响着患者的肺功能及气道的反应性。     

血清1,25-双羟维生素D3水平与绝经期哮喘急性发作的相关性研究

目的探讨血清1,25-双羟维生素D3(1,25-(OH)2-VitD3)水平与绝经期哮喘急性发作的相关性。方法收集2017年1月至2018年5月于我院住院符合纳入标准的绝经期哮喘急性发作患者40例作为实验组,同期收集符合纳入标准的我院健康体检者40例作为对照组。均采集空腹血标本,实验组于入院后次日晨采集,离心并收集血清,置于-70℃冰箱保存,后用酶联免疫吸附法(ELISA)检测血清1,25-(OH)2-VitD3水平。入院当天对实验组各研究对象进行ACT量表评分并当场收回,同时收集其入院时肺功能并记录FEV_1、FEV_1%预、FEV_1%FVC值。结果实验组血清1,25-(OH)2-VitD3水平明显低于对照组(P0.05)。绝经期哮喘急性发作患者血清1,25-(OH)2-VitD3水平与其ACT量表评分、肺功能(FEV_1、FEV_1%预、FEV_1%FVC)呈正相关(P0.05)。结论绝经期哮喘急性发作患者血清1,25-(OH)2-VitD3水平明显降低。血清1,25-(OH)2-VitD3水平越低,绝经期哮喘急性发作程度越重,肺功能越差。     

2型糖尿病患者血清25-羟维生素D和甲状旁腺激素水平与高血压病的相关性

目的探讨2型糖尿病患者血清25-羟基维生素D[25-(OH)D]、甲状旁腺激素(PTH)水平与其发生高血压的相关性。方法回顾性分析128例2型糖尿病住院患者,按照其是否合并原发性高血压病分为合并高血压组(89例)、无高血压组(39例)。收集研究对象的一般资料及检测血清PTH、25-(OH)D水平。分析25-(OH)D、PTH与2型糖尿病是否罹患高血压之间的关系。结果合并高血压组患者血清25-(OH)D水平低于无高血压组(P0.001)。两组间PTH水平差异无统计学意义(P=0.132)。Pearson相关性分析显示,25-(OH)D与PTH呈负相关(r=-0.182,P0.05)。二元Logistic回归分析显示25-(OH)D降低是2型糖尿病伴发高血压的危险因素(OR=0.935,95%CI 0.883～0.991,P=0.023),而PTH升高不是糖尿病患者易患高血压的危险因素。结论糖尿病患者易合并25-(OH)D降低,且25-(OH)D降低是糖尿病患者罹患高血压病的危险因素。     

老年高血压病患者颈动脉粥样硬化程度与血25-羟维生素D水平的相关性

目的　探讨老年高血压病患者颈动脉粥样硬化程度与血25-羟维生素D［25（OH）D］水平的相关性。方法　对2012年5月至12月间在宁波市第二医院就诊的老年高血压病患者经超声检测颈动脉内膜中膜厚度（IMT）,根据颈动脉IMT将患者分为颈动脉正常组（60例,对照组）、颈动脉内膜增厚组（60例）和颈动脉斑块组（60例）。采用ELISA法测定三组患者血清25（OH）D水平,分析25（OH）D水平与颈动脉IMT的关系。结果　颈动脉斑块组与颈动脉内膜增厚组血25（OH）D水平均低于颈动脉正常组（P<0.05）,颈动脉斑块组血25（OH）D水平低于颈动脉内膜增厚组（P<0.05）,差异均有统计学意义。结论　低血25（OH）D水平的老年高血压病患者具有颈动脉粥样硬化程度加重的危险,血25（OH）D水平测定有助于预测颈动脉粥样硬化程度。     

Relationship Among Pulmonary Function, Bronchial Hyperresponsiveness, and Atopy in Children with Clinically Stable Asthma

Pulmonary function testing plays a key role in the diagnosis and management of asthma in children. However, the literature does not clearly show whether children with clinically stable asthma have significantly reduced lung function when compared with normal children. We compared the lung function of 242 clinically stable asthmatic children who were initially diagnosed with mild intermittent or mild persistent asthma with the lung function of 100 nonasthmatic controls. The lung function was assessed using FEV₁, FEV₁/FVC, FEF_25–75 and PEF. In addition, we measured bronchial hyperresponsiveness (BHR) using the provocation concentration of methacholine needed to produce a 20% fall in FEV₁. All measures of pulmonary function were significantly decreased in the children with asthma. Pulmonary function was not influenced by atopy, serum IgE, or total eosinophil count (TEC). However, the likelihood ratio for trends revealed a significant association between our pulmonary parameters and the degree of BHR. Children with mild-to-severe BHR had greatly decreased lung function compared with those with normal BHR, the control group. In addition, a direct correlation was found between PC₂₀ and our pulmonary parameters in asthmatic children. However, only atopic children with asthma had a significant correlation between PC₂₀ and TEC. We found children with clinically stable asthma to have pulmonary obstruction, which associated strongly with their degree of BHR.     

Residual Abnormalities of Pulmonary Function in Asymptomatic Young Adult Asthmatics with Childhood-Onset Asthma

We investigated the pulmonary function of male asthmatics with childhood-onset asthma. Our results revealed that adult asthmatics with mild symptoms apparently have abnormal pulmonary function. On the other hand, after a 3-6-month symptom-free period, and even after inhalation of bronchodilator, they still showed significant residual abnormalities in pulmonary function. Pulmonary function tests are very sensitive tools for the assessment of airway limitations during an acute asthmatic attack. However, these tests are not sensitive enough to detect residual abnormalities in asymptomatic asthmatics. Although the positive predictive rate for detecting small airway dysfunction in asymptomatic asthmatics is not high, FEF_25-75 proved to be the best (63.2%) among the conventional pulmonary function parameters. We therefore suggest using FEF_25-75 instead of FEV₁ or peak flow rate in clinical practice for the conventional assessment of effectiveness of treatment, especially in the follow-up of asthmatic patients. More sensitive and simple tests are required in the future for detection of small airway dysfunction in asymptomatic asthmatics. Moreover, strict and early treatment of this abnormality with steroids is mandatory to prevent the formation of sequelae.     

Long-term Follow-up of Pulmonary Function in Bronchial Asthma Patients Treated with Pranlukast

Clinical studies have shown that pranlukast, a selective cysteinyl leukotriene antagonist, is effective for bronchial asthma. In the present paper, we retrospectively analyzed long-term asthma control by pranlukast treatment in patients treated with inhaled corticosteroids. We analyzed medical records and asthma diaries of 21 patients (9 males, 12 females) (52.1 ± 3.5 years of age) with bronchial asthma who experienced increase of more than 10 L/min in peak expiratory flow in the first 4 weeks of treatment with pranlukast (450 mg/day) and were subsequently treated with pranlukast for more than 1 year. They all received inhaled corticosteroids (400–1600 µg/day of beclomethasone dipropionate or equivalent). We examined clinical control in terms of time course of self-monitored peak expiratory flow. During the analyzed period, the dose of inhaled corticosteroids was tapered in 4 patients, constant in 15 patients and increased in 2 patients. In 19 patients treated with unchanged or tapered dose of inhaled corticosteroids, improvement in the increase of mean PEF at 4-week treatment was maintained for 1 year. No difference in the add-on effect of pranlukast was observed in patients treated with less than 800 µg and more than or equal to 800 µg of inhaled corticosteroids. Four patients underwent reduction of inhaled corticosteroids in the analyzed period and PEF was well-maintained and even increased by pranlukast treatment. In 11 patients in whom data for 3 years were available, the improvement in PEF persisted for 3 years. Although the present investigation is a retrospective analysis, these data may suggest that pranlukast has no tachyphylaxis and its effect continues for more than 1 year.     

冠心病患者血清25(OH)D水平的改变及其与冠状动脉病变严重程度的相关性

目的探讨冠心病患者血清25(OH)D水平的改变并分析其与冠状动脉病变程度的相关性。方法选择150例行冠状动脉造影患者,记录所有入选患者的一般情况,包括性别、年龄、高血压和糖尿病病史等情况。采用免疫透析比浊法测定生化指标,包括空腹血糖、低密度脂蛋白胆固醇(LDLC)、血清钙。所有患者均通过高效液相色谱-串联质谱法测定血清25(OH)D水平。根据造影结果,把患者分为正常对照组和冠状动脉病变组,冠状动脉病变组根据SYNTAX评分分为轻度、中度和重度三个亚组。结果冠心病患者血清25(OH)D水平(13.87±7.16μg/L)显著低于正常对照组(21.67±7.38μg/L,P0.05)。冠状动脉病变SYNTAX积分≥33分组(重度组)、23~32分组(中度组)和≤22分组(轻度组)血清25(OH)D水平均明显低于正常对照组(P0.05),且随冠状动脉病变SYNTAX积分增加(病变程度加重)血清25(OH)D水平逐渐降低(P0.05)。血清25(OH)D水平与冠状动脉病变严重程度呈显著负相关(r=-0.328,P=0.019)。所有患者LDLC、血糖及血清钙水平分别为2.90±0.98 mmol/L、5.85±1.46 mmol/L、2.09±0.22 mmol/L。双变量相关性分析示25(OH)D水平与患者年龄、LDLC、血糖及血清钙无明显相关性。结论血清25(OH)D水平在冠心病患者中显著降低,且其水平与冠状动脉病变严重程度密切相关。     

血清25(OH)D_3水平在哮喘发作期、治疗后的变化及与肺功能的相关性分析

目的探讨哮喘患者急性期及治疗后血清25(OH)D_3水平与肺功能及病情的相关性。方法选取来我院诊治的急性发作期哮喘患者60例为研究组,分为成年亚组及未成年亚组各30例,于治疗前及治疗后7d(缓解期),治疗后3个月测定其血清25(OH)D_3水平、第1秒用力呼气容积占预计值百分比(FEV1%pred)、呼气峰流速(PEF),于治疗前及治疗3个月后进行哮喘控制评分(ACT);于上述时间点选择健康人群为对照组测量相应指标,比较健康与患病人群两亚组间各项指标差异,并分析治疗前及3个月后研究组两亚组血清25-(OH)D_3水平与其他指标间的相关性。结果治疗前发作期、开始治疗后7d及3个月,对照组与研究组各亚组之间,各指标均有显著差异;而研究组治疗7d后血清25(OH)D_3水平也远高于治疗前。治疗前两亚组血清25(OH)D_3与FEV1%pred、PEF间无明显相关性;而开始治疗3个月后,两亚组血清25(OH)D_3与FEV1%pred、PEF及ACT评分均有显著正相关(未成年r=0.81,0.79,0.82;P均0.05;成年组r=0.61,0.54,0.70;P均0.05)。结论哮喘患者发作、缓解及稳定期血清25(OH)D_3水平在病情的诊断与预后评估中能发挥重要作用,值得进一步大样本深入研究。     

重症肺炎患者血清25-OH维生素D水平及其影响因素分析刘志远

目的 分析重症肺炎患者血清25-OH 维生素D(25-OH VitD) 水平及其相关影响因素。方法 选择本院ICU住院的125例重症肺炎组患者和体检中心50例健康对照组人群作为研究对象。采用酶联免疫吸附法(ELISA)检测两组研究对象血清25-OH VitD的水平,用多因素Logistic回归分析进行影响因素分析。结果 重症肺炎组患者维生素D缺乏患病率为68%(85/125),对照组维生素D缺乏患病率22% (11/50),两组差异具有统计学意义(c₂=30.52,P=0.000,P＜0.05)。重症肺炎组患者和对照组人群血清25-OH VitD水平分别为33.4±17.7nmol/L,51.2±21.1nmol/L,两组相比差异具有统计学意义(t=-5.68,P＜0.01)。重症肺炎组患者血清25-(OH)VD水平在性别、年龄、肺部疾病病史、器官功能障碍数目、长期卧床史之间差异均存在统计学意义(P＜0.05)。多因素Logistic回归分析结果表明：25-(OH)VD与性别、年龄、肺部疾病史、长期卧床史有关。结论 重症肺炎患者血清25-(OH)VD水平较低,25-(OH)VD与性别、年龄、肺部疾病史、长期卧床史有关。     

The Decline of Pulmonary Function Among Patients with Chronic Asthma Treated with Inhaled Corticosteroid

We analyzed the rate of decline of pulmonary function annually over 2 years in 49 patients with chronic asthma, who were being treated with inhaled corticosteroid (beclomethasone). The coefficient of linear regression of pulmonary function based on dose of inhaled corticosteroid may be used to track the exact rate of the decline of pulmonary function. The declining rate of pulmonary function is faster in the early stages of the disease, in spite of the treatment with inhaled beclomethasone. In chronic asthmatics, the distal airway units appear to deteriorate, and the extent of deterioration probably changes with the progression of the disease.     

Serum Eosinophil-Derived Neurotoxin (EDN) in Diagnosis and Evaluation of Severity and Bronchial Hyperresponsiveness in Childhood Asthma

This study sought to evaluate the use of serum eosinophil-derived neurotoxin (EDN), which has been proposed as a marker of airway inflammation in asthma in the diagnosis and evaluation of the severity and bronchial hyperresponsiveness in childhood asthma. We studied 72 children with atopic asthma, 36 children with nonatopic asthma, and 43 healthy controls. Skin prick tests, pulmonary function tests, and methacholine challenge tests were performed, in addition to total eosinophil count, serum ECP, and EDN being measured in all subjects. EDN levels were significantly higher in the atopic asthma group than those in the nonatopic asthma group or control group (p < 0.001), as were ECP levels (p < 0.001). EDN levels differed more significantly among groups divided by asthma severity (p < 0.001) than did ECP levels for these groups (p < 0.05). For the groups divided according to bronchial hyperresponsiveness, both EDN and ECP levels were significantly different (p < 0.005 and p < 0.01, respectively). Significant correlations were found between EDN and PC₂₀ (γ = −0.281; p < 0.001), between ECP and PC₂₀ (γ = −0.274; p < 0.005), and between EDN and ECP (γ = 0.443; p < 0.001). In conclusion, serum EDN, as another marker of eosinophilic inflammation together with ECP, may aid in the diagnosis of asthma, especially atopic asthma, and in the evaluation of the severity and bronchial hyperresponsiveness in childhood asthma.     

原发性高血压患者血清1,25二羟维生素D水平的相关性研究

目的:探讨原发性高血压患者血清1,25二羟维生素D水平与健康人群的差异,及可能影响1,25二羟维生素D水平的因素。方法 :随机选取原发性高血压患者124例(高血压组)与血压正常的健康人58例(对照组),进行血肌酐、血清1,25-二羟维生素D、肾素、钙离子水平测定和对比分析。结果 :与对照组比较,高血压组的血肌酐水平显著升高[(81.91±30.75)μmol/L比(76.53±11.77)μmol/L]及肾素[(3.14±9.22)ng/ml.h比(0.43±0.22)ng/ml.h],差异具有统计学意义(均P<0.01),1,25-二羟维生素D水平降低[(38.72±8.02)pg/ml比(39.59±11.53)pg/ml],差异具有统计学意义(P<0.05)。两组的钙离子浓度无差异。Pearson分析显示血肌酐水平与血清1,25-二羟维生素D水平存在负相关(r=-0.15,P<0.05)。结论 :高血压患者的1,25二羟维生素D水平显著低于健康人群。     

Serum 25-Hydroxyvitamin D Level and Kidney Function Decline in a Swiss General Adult Population

Background and objectives

Molecular evidence suggests that levels of vitamin D are associated with kidney function loss. Still, population-based studies are limited and few have considered the potential confounding effect of baseline kidney function. This study evaluated the association of serum 25-hydroxyvitamin D with change in eGFR, rapid eGFR decline, and incidence of CKD and albuminuria.

Design, setting, participants, & measurements

Baseline (2003–2006) and 5.5-year follow-up data from a Swiss adult general population were used to evaluate the association of serum 25-hydroxyvitamin D with change in eGFR, rapid eGFR decline (annual loss >3 ml/min per 1.73 m²), and incidence of CKD and albuminuria. Serum 25-hydroxyvitamin D was measured at baseline using liquid chromatography–tandem mass spectrometry. eGFR and albuminuria were collected at baseline and follow-up. Multivariate linear and logistic regression models were used considering potential confounding factors.

Results

Among the 4280 people included in the analysis, the mean±SD annual eGFR change was −0.57±1.78 ml/min per 1.73 m², and 287 (6.7%) participants presented rapid eGFR decline. Before adjustment for baseline eGFR, baseline 25-hydroxyvitamin D level was associated with both mean annual eGFR change and risk of rapid eGFR decline, independently of baseline albuminuria. Once adjusted for baseline eGFR, associations were no longer significant. For every 10 ng/ml higher baseline 25-hydroxyvitamin D, the adjusted mean annual eGFR change was −0.005 ml/min per 1.73 m² (95% confidence interval, −0.063 to 0.053; P=0.87) and the risk of rapid eGFR decline was null (odds ratio, 0.93; 95% confidence interval, 0.79 to 1.08; P=0.33). Baseline 25-hydroxyvitamin D level was not associated with incidence of CKD or albuminuria.

Conclusions

The association of 25-hydroxyvitamin D with eGFR decline is confounded by baseline eGFR. Sufficient 25-hydroxyvitamin D levels do not seem to protect from eGFR decline independently from baseline eGFR.